UPDATE 1-U #cadence #pharma

Posted On Sep 8 2017 by

#raptor pharma # UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources (Adds share reaction, more details) April 6 (Reuters) – Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development …


UPDATE 1-U #pharmaceutical #contract #manufacturer

Posted On Apr 12 2017 by

#raptor pharma # UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources (Adds share reaction, more details) April 6 (Reuters) – Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development …


UPDATE 1-U #pharma #digital #marketing

Posted On Mar 20 2017 by

#raptor pharma # UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources (Adds share reaction, more details) April 6 (Reuters) – Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development …


UPDATE 1-U #euro #pharma

Posted On Dec 20 2016 by

#raptor pharma # UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources (Adds share reaction, more details) April 6 (Reuters) – Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development …


UPDATE 1-U #hra #pharma

Posted On Oct 7 2016 by

#raptor pharma # UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources (Adds share reaction, more details) April 6 (Reuters) – Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development …


UPDATE 1-U

Posted On Sep 29 2016 by

#raptor pharma # UPDATE 1-U.S. drug developer Raptor Pharmaceuticals explores sale -sources (Adds share reaction, more details) April 6 (Reuters) – Raptor Pharmaceutical Corp, a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development …